Is There an Optimal Curative Option in HIV-Positive Men with Localized Prostate Cancer? A Systematic Review

John Baladakis\textsuperscript{a,b,c}, Marlon Perera\textsuperscript{d,e}, Damien Bolton\textsuperscript{d,f}, Nathan Lawrentschuk\textsuperscript{d,f,g}, Ahmed Adam\textsuperscript{a,b,c}

\textsuperscript{a}Department of Urology, Helen Joseph Hospital; \textsuperscript{b}Department of Pediatric Urology, Rahima Moosa Mother & Child (Coronation) Hospital; \textsuperscript{c}Division of Urology, Department of Surgery, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa; \textsuperscript{d}Department of Surgery, Austin Health, University of Melbourne, Melbourne, VIC; \textsuperscript{e}Department of Surgery, University of Queensland, Brisbane, QLD; \textsuperscript{f}Olivia-Newton John Cancer Centre, University of Melbourne, Melbourne, VIC; \textsuperscript{g}Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Abstract

Aims: We aimed to compare the outcome of curative treatment options in localised Prostate Cancer (PCa) amongst HIV positive (HIV+) men. Methods: A systematic search of the Cochrane Library of Systematic Reviews, the Scopus and PubMed databases was performed (January 1995 to November 2015) using pre-determined search terms. Outcome measures for comparison included the rate of biochemical failure (BCF), survival benefit and complications. Results: A total of 14 eligible articles were identified for inclusion, representing a total of 202 HIV+ men with PCa. Radical Prostatectomy was performed in 40/153 compared to 109/153 patients undergoing alternative (non-surgical) treatments options. Only 3 studies compared outcomes within their respective study cohort. One study (n = 10) reported BCF results with 1/2 BCF patient in the surgical arm vs. 1/8 BCF positive patients in the non-surgical arm (mean 46 months follow-up), while two other studies reported no occurrences of BCF within both arms of their studies. Conclusion: Due to paucity in the literature, there is insufficient evidence to support a certain treatment modality arm specifically for HIV+ men with localized PCa. An individualized management algorithm seems feasible within this cohort, until more definitive studies are performed.
may be due to HIV-infected men presenting at a relatively younger age, with more advanced disease stage when compared to the general population [4]. The hormonal effect of testosterone in the HIV-infected population due to hypogonadism may also play a role in the pathogenesis of this malignancy [5]. A trend has been noted that HIV+ men more frequently received radiation for the management of prostate cancer (PCa) and less frequently received surgery [2]. A recent review and meta-analysis have reviewed the outcomes of surgery versus radiotherapy for clinically localized PCa, and observed a higher mortality in the radiotherapy treatment arm [6].

Active treatment for PCa, including prostatectomy, has consistently been shown to provide a survival benefit in men with optimistic life expectancies [7]. Accordingly, has consistently been shown to provide a survival benefit for localized PCa amongst HIV+ men. Specifically, we aimed to review the rate of biochemical failure (BCF), survival benefit and complications.

Material and Methods

Search Strategy

A systematic review was performed in accordance with Cochrane Collaboration and Preferred Reporting Items for Systematic Review and Meta-Analysis Guidelines [8]. Scientific literature databases (MEDLINE, Scopus and the Cochrane Library) were systematically searched in December 2015 using several keywords, including: (“prostate” or “prostate cancer” or “prostate neoplasm” or “prostate malignancy”), (“human immunodeficiency virus” or “HIV” or “acquired immunodeficiency disease” or “AIDS”), “prostatectomy”, “radiotherapy”, “active surveillance” and “treatment”.

Both retrospective and prospective studies as well as clinical trials assessing the curative treatment for HIV+ patients with PCa were included in the current study. Articles involving non-curative, metastatic, or palliative treatment were excluded. The concept of active surveillance was considered as a “treatment” modality within the confines of this study. Journal article abstracts were screened for inclusion and suitability. Full-text papers were retrieved for all of the relevant articles. The study selection was independently performed by 2 reviewers (A.A., J.B.). Discrepancies in selection were solved by discussion, or group consensus.

Primary outcomes for the current study included BCF and outcome measures of the included studies precluded meta-analytical assessment. Extracted data were collated in Excel 2007 (Microsoft Corporation, Redmond, CA).

Results

Search Strategy

Using the systematic search strategy outlined, 2,796 articles were identified, of which 2,664 were not suitable for full-text review. Of the remaining 132, 75 were duplicate publications and 43 did not meet the inclusion criteria of the study (fig. 1). Thus, 14 relevant studies were included in this review. The relevant study inclusion categories, grade, and treatment modalities utilized and subsequent outcomes are summarized in table 1 (demographic data) and table 2 (outcome stratification).

This review, represented a total of 153 individual patients, since an additional 49 patients from Riedel et al. [4] could not be included in table 2 due to a paucity of treatment details. A total of 2 studies evaluating 13 men, assessed the surgical outcome. A further 6 studies assessed the non-surgical modalities, assessing 48 men in total. Five studies involved both surgical and non-surgical management and included 92 patients.

Quality Appraisal Results

Each relevant study was scored using the CASP cohort study checklist [9]. Scoring was performed by 2 evaluators (A.A., J.B.) and any discrepancies were resolved by
| Author | Country | n  | Race   | Age | Mean CD4 cells/ml | Viral load copies/ml | HARRT, n | PSA at diagnosis ng/ml | Gleason score | T stage | Risk categories |
|--------|---------|----|--------|-----|-------------------|---------------------|----------|-----------------------|--------------|---------|------------------|
| Ong et al. | Victoria, Australia | 12 | NS     | 62.7 | 559.4            | 8/12 UD, 4/12 2b–3c, 200 | 12       | mean (11.1) | 3 + 3 | 4 | T1c 7 D’Amico |
| Riedel et al. | Baltimore, UK | 49 | mixed 45 AA 4 CA | 60.7 | 391            | 37/49 < 400 8/49 > 400 | 47       | mean (82) MD (7.7) | mean median range 5–10 | T1 20 NS |
| Murphy et al. | Chicago, US | 43 | mixed 15 AA 24 CA 4 UN | 59.2 | 459.5 (MD) 37/43 < 500 6/43 > 500 | 41 | MD (5.9) | NS | T1 24 NCCN |
| Schreiber et al. | Brooklyn, US | 15 | mixed 12 AA 1 CA 2 HI | 65 | 464.2            | 11/15 UDU 4/15 90–70, 276 | 13       | < 10 (11) 10.1 to 20 (3) > 20 (1) | ≤ 8 | T1c 24 NS |
| Kahn et al. | Atlanta, US | 13 | mixed | 55 | 412.5            | 5/13 UDU 8/13 418–20, 21, 18 | 9       | < 10 (11) 10 to 20 (2) > 20 (0) | < 8 | T1c 10 NS |
| Silberstein et al. | San Diego, US | 8 | 5 AA 3 CA | 54.5 | 634            | 8/8 UD, 50 | 8 | mean (6) MD (5.6) | ≤ 8 | T1b-c 5 NS |
| Wisnitzer et al. | New York, US New York, US | 4 | NS 3 NS | 53 | 543            | 138 | 2 | mean (7.9) | NS | T1c 4 NS |
| Nget al. | New York, US | 14 | NS | 61 | 523            | 9/14 UDU 5/14 1,600–27,000 | 11       | mean (14.3) | ≤ 7 | T1c 6 NS |
| Pantanowitz et al. | Burlington, Chicago, Boston, Seattle, US | 16 | 3 AA 8 CA 2 HI 1 HA 2 UN | 59 | 336            | 17/319 | 14 | mean (30) | mean 6.8 | T1 7 NS |
| Walters et al. | London, UK | 1 | NS | 59 | 300            | UD, 1 | 1 | mean (7.9) | 4 + 3 | 4 | T2 1 NS |
| Huang et al. | New York, US | 5 | NS | 52 | 617.4            | 3/5 UD, 2/5 3,600–18, 700 | 3       | mean (11.26) | 3 + 3 | 4 | T1c 3 NS |
| O’Connor et al. | New Orleans, US | 3 | 2 AA 1 CA | 55.3 | 331            | 2/3 400–37,000 | 3 | mean (5.1) | 6 | 2 | T1c 1 NS |
| Quian et al. | London, UK | 2 | NS | 61 | 420.5            | 1/2 124 1/2 NS | 2 | mean (2.821, 3) | 3 + 2 | NS | T1c 1 NS |
| Levinson et al. | New York, US | 10 | 6 AA 2 CA 2 HI | 54 | 417            | UD, 9 | 9 | mean (9.2) | 5 | 6 | T2a 7 NS |

AA = African American; CA = Caucasian; HI = Hispanic; HI = Intermediate; HI = Low; M = Metastatic; MD = Median; NS = Not Stated; UD, = Undetectable < 20 copies/ml; UD, = Undetectable Not Defined; UN = Unknown.
Table 2. The outcomes within the studies reviewed

| Author          | Palliative treatment/ non-localized disease | Curative treatment modality used | Mean follow-up | Outcome |
|-----------------|-------------------------------------------|---------------------------------|----------------|---------|
|                 |                                           | Total                           | BCF RP positive | BCF Non-RP positive | RP | Non-RP |
| Ong et al. [10] | 1 WW                                      | 2 RP                            | 12             | 46                  | 1/2 | 1/8    | 2/2 RP clear surgical margins. 1/2 RP, put on salvage EBRT. |
|                 | 1 metastatic                              | 1 BT                            | 5 EBRT         | 1 AS                | 1 EBRT & ADT  | 1/5 curative EBRT pts developed BCF (based on phoenix definition). Three deaths reported, none of which were PCa-related deaths |
| Riedel et al. [4] | NS                                       | NS                              | NS             | 32.4                | NS          | By the end of the study period, 13 (27%) patients had died (8 patients [16%] of the cancer they had). Cumulative 5-year mortality was 22%. whereas CSS was 74% at 5 years. Mortality was higher in patients with stage III–IV disease compared with that in patients with stage I-II disease. |
| Schreiber et al. [12] | 0                                      | 10 EBRT & ADT                  | 15             | 52.67               | 0           | 2/15   | 2 BCF (28 and 63 months). 0/2 had evidence of metastatic disease. BCF negative (5-year) 92.3%. Acute GU toxicity: 4 Grade 1, 4 Grade 2, 1 Grade 3. Late GU toxicity: 2 Grade 2, 1 Grade 3. Acute GI toxicity: 4 Grade 2 Late GI toxicity: 1 Grade 3 4-year BCF -ve survival rate = 87% in the HIV+ group elevated pre- and post-EBRT VL were found to be significant risk factors for BCF: Acute GU toxicity: 3 Grade 1, 4 Grade 2 Late GU toxicity: 4 Grade 1, 1 Grade 3 Acute GI toxicity: 4 Grade 1, 1 Grade 3 Late GI toxicity: 2 Grade 1 HIV positivity and the use of intensity-modulated radiation therapy were found to be protective of acute GU toxicities. 11/13 pts CD4 declined post EBRT. |
| Kahn et al. [13] | 0                                        | 1 EBRT & ADT                    | 13             | 39                  | 0           | 2/13   | 4-year BCF -ve survival rate = 87% in the HIV+ group elevated pre- and post-EBRT VL were found to be significant risk factors for BCF. Acute GU toxicity: 3 Grade 1, 4 Grade 2 Late GU toxicity: 4 Grade 1, 1 Grade 3 Acute GI toxicity: 4 Grade 1, 1 Grade 3 Late GI toxicity: 2 Grade 1 HIV positivity and the use of intensity-modulated radiation therapy were found to be protective of acute GU toxicities. 11/13 pts CD4 declined post EBRT. |
| Silberstein et al. [14] | 0                                      | 8 RALP                          | 8              | 5.6                 | 0           | 0      | 8/8 pts had negative margins. No significant differences in the prevalence of overall, low-grade, or high-grade complications between HIV+ and HIV-. All patients achieved undetectable serum PSA levels; no recurrence |
| Wosnitzer et al. [15] | 0                                      | 4                                | 4              | 18.5 (MD)           | 0           | 0      | All patients achieved undetectable serum PSA levels; no recurrence All patients had stable post EBRT PSA levels; no recurrence. No major complications. Post BT: 2/4 serum PSA of < 0.1 ng/ml 1/4 had a stable PSA level of 3.56 ng/ml 1/4 lost to follow-up, no recurrences |
| Ng et al. [16]  | 0                                        | 4 BT                            | 14             | 26                  | 0           | 1/14   | 13/14 pts PSA decline to 1.1 ng/ml or below. 1/14 PSA elevation and suspicious bone lesion |
Table 2. The outcomes within the studies reviewed

| Author            | Palliative treatment/ non-localized disease | Curative treatment modality used | Mean follow-up Total | BCF RP positive | BCF Non-RP positive | Outcome | RP | Non-RP |
|-------------------|--------------------------------------------|---------------------------------|----------------------|----------------|---------------------|---------|----|--------|
| Pantanowitz et al. [5] | 1                                          | 7 ADT & EBRT                    | 16                   | NS             | 0                   | Complete response in all patients treated. Underdetectable PSA and the absence of tumour recurrence. |    |     |        |
| Walters et al. [17]| 0                                          | 1 ADT                           | 1                    | 34             | 0                   |         | 0  |        |
| Huang et al. [18]  | 0                                          | 2 ADT                           | 5                    | 26             | 0                   | 1/5 positive lymph node and extracapsular extension 0/5 BCF at follow-up. 2/5 Wound infections |    |     |        |
| O’Connor et al. [19]| 0                                         | 1 EBRT & ADT                    | 3                    | 1              | 0                   |         | 0  |        |
| Quatan et al. [20] | 1                                          | 1 EBRT & ADT                    | 1                    | 36             | 0                   |         | 0  |        |
| Levinson et al. [21]| 1 MIRP                                     | 1 CRY                           | 10                   | 27.6           | 0                   | 0/1 BCF at follow-up 1/1 gynecomastia due to ADT |    |     |        |

ADT = Androgen deprivation therapy; AS = active surveillance; BT = brachytherapy; CRY = cryo-surgery; CSS = cancer specific survival; EBRT = external beam radiotherapy; MD = median; MIRP = minimally-invasive radical prostatectomy; NS = not stated; RP = radical prostatectomy; WW = watchful waiting.

Table 3. Quality appraisal results tabulated, utilizing the closed ended questions of the CASP cohort study checklist [9]

| Question | Ong et al. [13] | Riedel et al. [14] | Murphy et al. [11] | Schreiber et al. [12] | Kahn et al. [13] | Silbersiein et al. [14] | Wosnitzer et al. [15] | Ng et al. [16] | Pantanowitz et al. [5] | Walters et al. [17] | Huang et al. [18] | O’Connor et al. [19] | Quatan et al. [20] | Levinson et al. [21] |
|----------|-----------------|--------------------|--------------------|-----------------------|-----------------|------------------------|----------------------|----------------|------------------------|----------------------|------------------|---------------------|---------------------|---------------------|
| 1        | Did the study address a clearly focused issue? | Y                  | Y                  | Y                    | Y                | Y                      | Y                    | Y              | Y                      | Y                    | Y                | N                   | Y                   | N                   |
| 2        | Was the cohort recruited in an acceptable way? | Y                  | Y                  | Y                    | Y                | Y                      | N                    | Y              | Y                      | Y                    | Y                | N                   | Y                   | N                   |
| 3        | Was the outcome accurately measured to minimize bias? | Y                  | Y                  | Y                    | Y                | Y                      | N                    | Y              | Y                      | Y                    | N                | N                   | N                   | N                   |
| 4        | Was the follow-up long enough? | Y                  | Y                  | Y                    | Y                | Y                      | Y                    | Y              | Y                      | Y                    | Y                | N                   | Y                   | Y                   |
| 5a       | Have the authors listed all confounding factors? | Y                  | Y                  | Y                    | Y                | N                      | N                    | N              | N                      | N                    | N                | N                   | N                   | N                   |
| 5b       | Have the authors taken account of all the confounding factors? | Y                  | Y                  | Y                    | Y                | Y                      | N                    | N              | N                      | N                    | N                | N                   | N                   | N                   |

ADT = Androgen deprivation therapy; AS = active surveillance; BT = brachytherapy; CRY = cryo-surgery; CSS = cancer specific survival; EBRT = external beam radiotherapy; MD = median; MIRP = minimally-invasive radical prostatectomy; NS = not stated; RP = radical prostatectomy; WW = watchful waiting.
consensus. For ease of reference, results of the quality appraisal have been tabulated (table 3).

**Patient Demographics and HIV/AIDS Status**

Of the included 14 studies, the respective mean ages of the cohort ranged between 52 and 65 years. Regarding the patient’s HIV/AIDS status, mean CD4 count of the included studies ranged between 300 and 1,417 cells/ml. Of the included 202 patients, the proportion of patients actively receiving HAART was 89.1%. Mean duration of HAART was poorly reported across all studies. These findings are summarized in table 1.

**PCa Characteristics**

Of the included studies, mean serum prostate-specific antigen ranged between 5.1 and 82 ng/ml. PCa risk stratification was heterogeneous and poorly reported across the studies, with several publications utilizing the National Comprehensive Cancer Network risk tool [11] or D'Amico scoring system [10, 12, 14].

Including the demographic data from Riedel et al. [4], of the 202 patients, histopathologically, a vast majority represented pT1 disease (54.5%) with the remainder pT2 (30.2%), pT3 (7.9%), pT4 (4.0%) or unknown (3.4%). Of the included patients, tumors were characterized as Gleason < 7 in 17.3%, Gleason 7 in 17.8%, Gleason > 7 in 5.4% and unknown in 59.9%. These findings are summarized in table 1.

**PCa Treatment and Oncological Outcomes**

Regarding treatment, 40/153 underwent radical prostatectomy with curative attempt. Studies reported this as being performed as robotic-assisted laparoscopic prostatectomy (RALP), minimally-invasive radical prostatectomy or otherwise unspecified. The remainder of the patients received either external beam radiotherapy, brachytherapy or active surveillance.

Mean follow-up ranged 1–90 months post-operatively. During this follow-up period, 7 patients experienced BCF. Of these 1/40 was from the prostatectomy group and 6/109 were from patients that underwent other forms of curative treatment for PCa. A lack of comparative series precluded the calculation of pooled hazards ratios.

**Discussion**

Recent therapeutic advancements in the management of HIV/AIDS has resulted in a significant improvement in life expectancy in these patients. As a result of less toxic antiretroviral drugs, improved adherence and management of comorbid disease, it is thought that previously described prognostic models and life expectancy estimates for HIV+ patients should be revised [22]. Accordingly, treatment of relatively indolent cancers, such as low and intermediate risk PCa are becoming more relevant. In addition, the increased use of prebiopsy multiparametric magnetic resonance imaging is resulting in more clinically relevant PCa in newly diagnosed patients [23, 24] and thus possibly more HIV+ patients requiring intervention. Our systematic review has highlighted the fact that such patients may exhibit acceptable oncological outcomes when treated with curative measures.

Traditionally, curative treatment for PCa is reserved for patient with a life expectancy of greater than 10 years [25]. The rapid improvement in HAART has improved the life expectancy of HIV+ patients, to the point where they may be considered for curative treatment for PCa. Indeed, the current review identified that of the treated patients, a majority were clinically low-to-intermediate risk. Specifically, of the reporting studies, patients were predominantly D’Amico or NCCN low or intermediate risk. Similarly, a majority of the patients were clinically stage T1. Such patient demographics highlight the nature of early intervention for HIV-infected patients with concurrent PCa.

The incidence of PCa is increasing globally and there is increased PCa mortality in all but the higher resource countries [26, 27]. With this fact in mind it is important to critically assess the available treatment options available for localized PCa in the growing number of HIV-infected men with PCa. Our study has highlighted that, while there is limited data to date, surgical and non-surgical treatment of PCa in this cohort results in acceptable oncological outcomes. This empiric data does not deter the surgical option in this select cohort of patients, as short-term data have not shown a significant difference in outcome based on HIV status. The data, although not reaching statistical significance, does seem to suggest a lower rate of radical prostatectomies being performed in the HIV+ population. The paucity of available evidence also suggests the dire need for further research into this population subgroup, which will increase in number and significance due to the efficacy of HAART therapy.

The differences in the management of PCa in HIV+ infected men when compared to HIV- men may indicate treatment disparities, although some studies have shown most HIV+ men were in fact treated in accordance with guidelines [11]. Some factors that may influence the decision to perform prostatectomy may include risk to the
surgical team and risk of operative complications. Furthermore, it is known that PCa decision aids may shift patients’ preference from prostatectomy to radiotherapy [28]. Despite the low risk of HIV transmission with needle stick injuries (< 0.09%) [29], it remains a concern for the treating clinicians. Some studies have suggested that RALP may limit the surgical teams exposure to blood and needle stick injury [18, 21]. It has also been shown that RALP has comparable oncological outcomes when compared to open surgery [30].

Silberstein et al. [14] found that HIV-infected individuals had a higher rate of peri-operative transfusion and ileus/small bowel obstruction, but had similar oncological outcomes and other peri-operative complications when compared to non-infected patients. Careful patient selection and assessment is suggested for this patient group including CD4+ counts, viral load, albumin levels, and clinical HIV staging [18]. Furthermore, focal therapy of PCa may be beneficial in this population of patients given the potential increased risk of more invasive treatment modalities, as it may be associated with reduced morbidity [24].

Patient anxiety based on the severity grade of the underlying cancer has been proven to increase in men with more severe PCa [31], however, the impact of concurrent HIV infection within this cohort corrected for grade, has not yet been specifically explored.

Our literature review does not support or refute the surgical treatment of localized PCa within HIV+ men. This is further confounded by the ongoing debate in the literature regarding the best practice in the treatment of high risk PCa in HIV- men [32]. However, an individualized treatment approach seems logical, with the following factors and risks taken into consideration; the CD4 count, viral load, presence of AIDS defining disease, cancer factors and histological subtype, patient comorbidity status, patient life expectancy, the surgeon experience and hazardous risk exposure and the availability of (equally effective) alternative therapeutic options. With the improvements in HAART, urologists may find themselves managing HIV+ patients with concurrent PCa more frequently. Further advances in the management of PCa, such as focal therapies [33], may further add to the armamentarium of treating clinicians within the near future.

**Conclusion**

The current available data reviewed does not support or discourage a particular treatment arm in localized PCa amongst HIV+ men, thus an optimal treatment modality can not be supported within this cohort of patients. Until better more defining studies are published, an individualized approach seems logical.

**Acknowledgments**

The authors wish to acknowledge the research assistance from Ms. Tshifhiwa Nkwenika, BSc, and Prof. Samuel Manda, PhD, from the Biostatistics Unit, Medical Research Council, Pretoria, South Africa. The authors are also indebted to Mrs. Anna Welman, Department of Surgery at the Helen Joseph Hospital, University of the Witwatersrand, Johannesburg, South Africa, for her secretarial support in the construction of this review.

**References**

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–860.
2. Marcus JL, Chao C, Leyden WA, Xu L, Yu J, Horberg MA, Kleiner D, Towner WJ, Quesenberry CP, Abrams DI, Silverberg MJ: Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev 2015;24:1167–1173.
3. Coghill AE, Shiels MS, Suneja G, Engels EA: Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 2015;33:2376–2383.
4. Riedel DJ, Cox ER, Stafford KA, Gilliam BL: Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African American, human immunodeficiency virus–infected patients. Urology 2015;85:415–421.
5. Pantanowitz L, Bohac G, Cooley TP, Aboulafia D, Dezube BJ: Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int 2008;101:1519–1523.
6. Wallis CJ, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK: Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;70:21–30.
Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Spängberg A, Andréon O, Palmgren J, Steineck G, Adami HO, Johansson JE: Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2535.

Critical Appraisal Skills Programme (CASP) 2014. CASP Checklists: http://www.casp-uk.net/casp-tools-checklists.

Ong WL, Manohar P, Millar J, Royce P: Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (HIV)-positive population: experience in an Australian major HIV centre. BJU Int 2015;116(suppl 3):5–10.

Murphy AB, Bhatia R, Martin IK, Klein DA, Hollowell CM, Nymme Y, Dieulabene E, Achenbach C, Kittles RA: Are HIV-infected men vulnerable to prostate cancer treatment disparities? Cancer Epidemiol Biomarkers Prev 2014;23:2009–2018.

Schreiber D, Chhabra A, Rineer J, Nabhani T, Katsoulakis E, Morkos R, Rotman M, Schwartz D: Outcomes and tolerance of human immunodeficiency virus-positive U.S. veterans undergoing dose-escalated external beam radiotherapy for localized prostate cancer. Clin Genitourin Cancer 2014;12:94–99.

Kahn S, Jani A, Edelman S, Rossi P, Godette K, Landry J, Anderson C: Matched cohort analysis of outcomes of definitive radiotherapy for prostate cancer in human immunodeficiency virus-positive patients. Int J Radiat Oncol Biol Phys 2012;83:16–21.

Silberstein JL, Parsons JK, Palazzi-Churas O, Doscott TM, Sakamoto K, Derweesh IH, Woldrich J, Kane CJ: Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus. Prostate Cancer Prostatic Dis 2010;13:328–332.

Wosnitzer MS, Lowe FC: Management of prostate cancer in HIV-positive patients. Nat Rev Urol 2010;7:348–357.

Ng T, Stein NF, Kaminetsky J, Berman S, Marans HY, McDermott B, Persson AM: Preliminary results of radiation therapy for prostate cancer in human immunodeficiency virus-positive patients. Urology 2008;72: 1135–1138.

Walters Z, Shamash J, Powles T: Prostate cancer in HIV-positive individuals: what we know and what we don’t. J HIV Ther 2007; 12:66–67.

Huang WC, Kwon EO, Scardino PT, Eastham JA: Radical prostatectomy in patients infected with human immunodeficiency virus. BJU Int 2006;98:303–307.

O’Connor JK, Nedzi LA, Zakris EL: Prostate adenocarcinoma and human immunodeficiency virus: report of three cases and review of the literature. Clin Genitourin Cancer 2006;5:85–88.

Quan T, Nair S, Harrowes F, Hay P: Should HIV patients be considered a high risk group for the development of prostate cancer? Ann R Coll Surg Engl 2005;87:437–438.

Levinson A, Nagler EA, Lowe FC: Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 2005;65:91–94.

Antiretroviral Therapy Cohort Collaboration: Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017;4:e349–356.

Carlaw KR, Woo HH: Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016. Prostate Int 2017;5:130–134.

Marshall S, Tanega S: Focal therapy for prostate cancer: the current status. Prostate Int 2015;3:35–41.

Mottet N, Bellmunt J, Bolla M, Briërs E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Mateev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618–629.

Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Autunen A: Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010;46:3040–3052.

Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60–67.

Tol-Gerzdekink JJ, Willem Leer J, Weijerman PC, Oort IM, Vergust H, Lin EN, Alfred Witjes J, Stalmieer PF: Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 2013;111:564–573.

Bell DM: Occupational risk of human immunodeficiency virus infection in health-care workers: an overview. Am J Med 1997;102(5B):9–15.

Vora AA, Marchalik D, Kowalczyk KJ, Nissim H, Bandi G, McGeagh KG, Lynch JH, Ghaseemian SR, Vergheese M, Venkatesan K, Borges P, Uchio EM, Hwang JJ: Robotic-assisted prostatectomy and open radical retropubic prostatectomy for locally-advanced prostate cancer: multi-institution comparison of oncologic outcomes. Prostate Int 2013;1:31–36.

Johannes C, Monoura RA, Ismail RI, Umbas R: Anxiety level of early- and late-stage prostate cancer patients. Prostate Int 2013;1:177–182.

Chung BH: The role of radical prostatectomy in high-risk prostate cancer. Prostate Int 2013;1:95–101.

Perera M, Krishnanathan N, Lindner U, Lawrentschuk N: An update on focal therapy for prostate cancer. Nat Rev Urol 2016;13:641–653.